Literature DB >> 27882428

Progression of noncalcified and calcified coronary plaque by CT angiography in SLE.

Aisha Khan1, Armin Arbab-Zadeh2, Adnan N Kiani1, Laurence S Magder3, Michelle Petri4.   

Abstract

Premature coronary artery disease remains the major cause of late death in systemic lupus erythematosus (SLE). Coronary artery calcium (CAC) represents an advanced stage of atherosclerosis, whereas noncalcified coronary atherosclerotic plaque (NCP) typically is more prone to trigger acute coronary events. The aim of this study was to assess the stability of NCP over time and identify factors associated with changes in NCP in patients with SLE. CT coronary angiography and calcium scanning were performed at baseline and follow-up in thirty-six SLE patients. Duration between baseline and follow-up NCP assessment ranged from 2 to 8 years. CAC was quantified by the Agatston score and classified as none, low (1-99), moderate (100-299) or high calcium score (300 and above). NCP was quantified based on a previously validated score and classified as none, low (<0.5) or high (0.5+). SLE disease activity was quantified using the SELENA-SLEDAI and physician global assessment indices. To assess the association between quantitative clinical variables and changes in NCP, adjusting for time, we used linear regression models. The group of 36 SLE patients were 75% females, 75% Caucasians, 17% African-Americans, 8% other ethnicities. The mean age of patients was 46.6 years. For NCP, 17/36 (47%) of the patients switched qualitative NCP class (none, low, high) between baseline and follow-up, whereas for CAC only 3/35 (9%) switched qualitative class. Increasing years between assessments were associated with an increase in NCP (P = 0.038). The proportion of time on immunosuppressants was associated with a decrease in NCP (P = 0.06). Calcified coronary plaque levels remained relatively stable over a period of 2-8 years. Noncalcified coronary plaque levels were more variable. Use of immunosuppressive drugs appeared to be protective against noncalcified coronary plaque progression.

Entities:  

Keywords:  Coronary plaque; Noncalcified coronary plaque; Systemic lupus erythematosus

Mesh:

Year:  2016        PMID: 27882428      PMCID: PMC5226869          DOI: 10.1007/s00296-016-3615-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  Composition of coronary atherosclerotic plaques in patients with acute myocardial infarction and stable angina pectoris determined by contrast-enhanced multislice computed tomography.

Authors:  Alexander W Leber; Andreas Knez; Carl W White; Alexander Becker; Franz von Ziegler; Olaf Muehling; Christoph Becker; Maximilian Reiser; Gerhard Steinbeck; Peter Boekstegers
Journal:  Am J Cardiol       Date:  2003-03-15       Impact factor: 2.778

2.  Associations between HIV infection and subclinical coronary atherosclerosis.

Authors:  Wendy S Post; Matthew Budoff; Lawrence Kingsley; Frank J Palella; Mallory D Witt; Xiuhong Li; Richard T George; Todd T Brown; Lisa P Jacobson
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

3.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

4.  Non-obstructive low attenuation coronary plaque predicts three-year acute coronary syndrome events in patients with hypertension: multidetector computed tomographic study.

Authors:  Koki Nakanishi; Shota Fukuda; Kenei Shimada; Shoichi Ehara; Hitoshi Inanami; Kenji Matsumoto; Haruyuki Taguchi; Takashi Muro; Junichi Yoshikawa; Minoru Yoshiyama
Journal:  J Cardiol       Date:  2012-01-14       Impact factor: 3.159

5.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors:  L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal:  Arthritis Rheum       Date:  2012-01

6.  Semiquantified noncalcified coronary plaque in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Jens Vogel-Claussen; Armin Arbab-Zadeh; Laurence S Magder; Joao Lima; Michelle Petri
Journal:  J Rheumatol       Date:  2012-10-01       Impact factor: 4.666

Review 7.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-11-27       Impact factor: 7.580

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus.

Authors:  Christophe Richez; Rocco J Richards; Pierre Duffau; Zachary Weitzner; Christopher D Andry; Ian R Rifkin; Tamar Aprahamian
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more
  5 in total

1.  Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus.

Authors:  Paola C Roldan; Ernest R Greene; Clifford R Qualls; Wilmer L Sibbitt; Carlos A Roldan
Journal:  Rheumatol Int       Date:  2019-03-16       Impact factor: 2.631

Review 2.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

Review 3.  Application of Non-invasive Imaging in Inflammatory Disease Conditions to Evaluate Subclinical Coronary Artery Disease.

Authors:  Harry Choi; Domingo E Uceda; Amit K Dey; Nehal N Mehta
Journal:  Curr Rheumatol Rep       Date:  2019-12-12       Impact factor: 4.592

4.  Soluble Tumor Necrosis Factor Receptor 1 is Associated With Cardiovascular Risk in Persons With Coronary Artery Calcium Score of Zero.

Authors:  Tony Dong; Graham Bevan; David A Zidar; Miguel Cainzos Achirica; Khurram Nasir; Imran Rashid; Sanjay Rajagopalan; Sadeer Al-Kindi
Journal:  Pathog Immun       Date:  2021-12-03

Review 5.  Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease.

Authors:  Mushrin Malik; Rajvi Gor; Nabeel A Siddiqui; Dhairya Gor; Kazi I Ahmed
Journal:  Cureus       Date:  2021-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.